Drugs / EVP-6308
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02037074 | Jun → Dec 2014 | schizophrenia | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT02001389 | Oct 2013 → Jun 2014 | — | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVP-6308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02037074 ↗ |
| Route | Oral | “ascending oral dose study” NCT02037074 ↗ |
| Target | PDE10A | “PDE10A Occupancy After Dosing With EVP-6308” NCT02001389 ↗ |